薬物のナノ粒子は血小板の集積と血液凝固を低下させた

Sarah Majin¹, Afrida Malik¹, Pratima Poudel¹

¹Department of Chemistry and Chemical & Biomedical Engineering, University of New Haven, West Haven, CT, United States.

Frontiers in medical technology

|February 20, 2026

まとめ

酸化窒素を放出するナノ粒子は,血小板の活性化と凝結を抑制することによって,血栓を効果的に予防します. これらの新しい抗血小板脂質ナノ粒子は,医療機器のための有望な解決策を提供します.

科学分野:

バイオマテリアルエンジニアリング
ナノテクノロジーナノテクノロジー
心血管科学の研究について

背景:

表面誘発性血栓症は,血液と接触する医療機器にとって大きな課題です.
血小板の活性化と血栓形成は,デバイスに関連した血栓形成の主要な要因です.
酸化窒素 (NO) は,治療の可能性のある天然の抗血小板剤です.

研究の目的:

酸化窒素を放出する抗血小板脂質ナノ粒子 (抗PLT LNPs) を開発し,特徴づけること.
抗PLT LNPの抗血小板剤および抗凝固剤の有効性を評価する.
ナノ粒子の生物互換性とNO放出運動性を評価する.

主な方法:

抗PLT LNPの製剤と物理化学的特徴.
血小板集積抑制のインビトロ評価.
活性化凝固時間 (ACT) を使用した哺乳類細胞の生物互換性と全血凝固の評価.

主要な成果:

Anti-PLT LNPは22週間にわたって持続的な酸化窒素の放出を示した.
ナノ粒子は,哺乳類の細胞生物互換性が高いことを示した.
血小板凝集の有意な抑制 (最大84.4%) と凝固時間の延長 (ACTの3倍まで増加).

結論:

NOを放出する抗PLT LNPは,血小板の活性化と凝固を効果的に抑制します.
ナノ粒子は生物互換性を維持し,血栓形成を緩和するためのターゲットを絞ったアプローチを提供します.
これらの発見は,血液と接触する医療機器を改善するための有望な戦略を示唆しています.

キーワード:

抗凝固剤として使われます.血液と接触する医療機器薬物の配達薬物の配達リポソームはリポソームである.ナノ粒子ナノ粒子酸化窒素は窒素酸化物である.血小板血小板血小板トロンボシス (血栓形成) とは

さらに関連する動画

09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.5K

06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

関連する概念動画

01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

1.4K

01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

2.1K

01:22

Formation of the Platelet Plug

9.8K

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

9.8K

01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

関連する実験動画